PTO/SB/21 (01-08)

Approved for use through 02/29/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 10/574,862 Filing Date TRANSMITTAL April 6, 2006 First Named Inventor **FORM** Pugia, et al Art Unit 1609 **Examiner Name** Sharon Wen (to be used for all correspondence after initial filing) Attorney Docket Number 017191.0049 Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)					
Fee	e Transmittal Form	Drawing(s)		After Allowance Communication to TC	
	Fee Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Exte	endment/Reply After Final Affidavits/declaration(s) ension of Time Request bress Abandonment Request formation Disclosure Statement attified Copy of Priority cument(s) bly to Missing Parts/ complete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Petition Petition to Convert to a Provisional Application Power of Attorney, Revocat Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on C	Address	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Acknowledgement postcard	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name Kelley Drye & Warren LL		P		,	
Signature Stand It. Mello					
Printed name Harold N. Wells					
Date February 27, 2008			Reg. No.	26,044	
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:					
Signature Chill Ebukut					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Heide Eberhart

Typed or printed name

Date

2/27/08





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

tent Application	Customer No.: 47670	
Michael J. Pugia, et al.)	
10/574,862) I hereby certify that this correspondence is) being deposited with the United Postal Service as First Class Mail in an envelope addressed to:	
April 6, 2006) Mail Stop AMENDMENT, Commissioner of) Patents, P. O. Box 1450, Alexandria, VA,	
Monoclonal Antibodies for Detection of Urinary Trypsin Inhibitors) 22313-1450, on February 27, 2008) (1) (1) (2) (2) (3) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4	
	Michael J. Pugia, et al. 10/574,862 April 6, 2006 Monoclonal Antibodies for Detection of Urinary Trypsin	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.97 and 1.98

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

In compliance with the duty of disclosure under 37 C.F.R. §1.56, it is respectfully requested that this Information Disclosure Statement be entered and the reference(s) listed on attached Form PTO-1449 be considered by the Examiner and made of record. Each of the references is a publication in which the first named inventor is an author and published in 2006 or 2007.

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), copies of the listed references are enclosed. In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information disclosed is, or is considered to be, prior art with respect to the present application or material to patentability as defined in 37 C.F.R. §§ 1.56.

The present Information Disclosure Statement is being filed before the mailing of a First Office Action after filing of an RCE in the subject application and hence is believed to be timely in accordance with 37 C.F.R. § 1.97(b)(4). Accordingly, no fees are believed to be due in connection with the filing of this Information Disclosure Statement. However, should any fees be deemed necessary (except payment of the issue fee), the Commissioner is authorized to charge any deficiency or to credit any overpayment to Kelley Drye & Warren LLP Account No. 11-0404/017191.0049.

Respectfully submitted,

Date

2/27/08

Harold N. Wells Reg. No. 26,044

Kelley Drye & Warren LLP

333 West Wacker Drive, Suite 2600

Chicago, IL 60606

(312) 857-2336

(312) 857-7095 (Fax)

Attorneys for Applicant